{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:45:28Z","timestamp":1790664328579,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T00:00:00Z","timestamp":1431561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T00:00:00Z","timestamp":1431561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One prerequisite that radiotherapy (RT) and chemotherapy (CT) result in anti-tumor immune responses is triggering of immunogenic cell death forms such as necroptosis. The latter is inducible by inhibition of apoptosis with the pan-caspase inhibitor zVAD-fmk. The design of multimodal therapies that overcome melanoma's resistance to apoptosis is a big challenge of oncoimmunology. As hints exist that immune stimulation by hyperthermia (HT) augments the efficacy of melanoma therapies and that tumors can be sensitized for RT with zVAD-fmk, we asked whether combinations of RT with dacarbazine (DTIC) and\/or HT induce immunogenic melanoma cell death and how this is especially influenced by zVAD-fmk. Necroptosis was inducible in poorly immunogenic B16-F10 melanoma cells and zVAD-fmk generally increased melanoma cell necrosis concomitantly with the release of HMGB1. Supernatants (SNs) of melanoma cells whose cell death was modulated with zVAD-fmk induced an upregulation of the activation markers CD86 and MHCII on macrophages. The same was seen on dendritic cells (DCs), but only when zVAD-fmk was added to multimodal tumor treatments including DTIC. DCs of MyD88 KO mice and DCs incubated with SNs containing apyrase did not increase the expression of these activation markers on their surface. The<jats:italic>in vivo<\/jats:italic>experiments revealed that zVAD-fmk decreases the tumor growth significantly and results in a significantly reduced tumor infiltration of Tregs when added to multimodal treatment of the tumor with RT, DTIC and HT. Further, a significantly increased DC and CD8+ T-cell infiltration into the tumor and in the draining lymph nodes was induced, as well as an increased expression of IFN<jats:italic>\u03b3<\/jats:italic>by CD8+ T cells. However, zVAD-fmk did not further reduce tumor growth in MyD88 KO mice, mice treated with apyrase or RAG KO mice. We conclude that HMGB1, nucleotides and CD8+ T cells mediate zVAD-fmk induced anti-melanoma immune reactions in multimodal therapy settings.<\/jats:p>","DOI":"10.1038\/cddis.2015.129","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T12:52:03Z","timestamp":1431607923000},"page":"e1761-e1761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner"],"prefix":"10.1038","volume":"6","author":[{"given":"N","family":"Werthm\u00f6ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U S","family":"Gaipl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,14]]},"reference":[{"key":"BFcddis2015129_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991\u2013998.","journal-title":"Nat Immunol"},{"key":"BFcddis2015129_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54\u201361.","journal-title":"Nat Med"},{"key":"BFcddis2015129_CR3","first-page":"1064","volume":"22","author":"JW Hodge","year":"2008","unstructured":"Hodge JW, Guha C, Neefjes J, Gulley JL . Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 2008; 22: 1064\u20131070.","journal-title":"Oncology (Williston Park)"},{"key":"BFcddis2015129_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fonc.2012.00075","volume":"2","author":"Y Rubner","year":"2012","unstructured":"Rubner Y, Wunderlich R, Ruhle PF, Kulzer L, Werthmoller N, Frey B et al. How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol 2012; 2: 75.","journal-title":"Front Oncol"},{"key":"BFcddis2015129_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0065-2776(04)84004-5","volume":"84","author":"L Zitvogel","year":"2004","unstructured":"Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G . Immune response against dying tumor cells. Adv Immunol 2004; 84: 131\u2013179.","journal-title":"Adv Immunol"},{"key":"BFcddis2015129_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/37022","volume":"390","author":"RE Voll","year":"1997","unstructured":"Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I . Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350\u2013351.","journal-title":"Nature"},{"key":"BFcddis2015129_CR7","first-page":"161","volume":"305","author":"US Gaipl","year":"2006","unstructured":"Gaipl US, Sheriff A, Franz S, Munoz LE, Voll RE, Kalden JR et al. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 2006; 305: 161\u2013176.","journal-title":"Curr Top Microbiol Immunol"},{"key":"BFcddis2015129_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.autrev.2008.07.049","volume":"8","author":"C Schulze","year":"2008","unstructured":"Schulze C, Munoz LE, Franz S, Sarter K, Chaurio RA, Gaipl US et al. Clearance deficiency\u2014a potential link between infections and autoimmunity. Autoimmun Rev 2008; 8: 5\u20138.","journal-title":"Autoimmun Rev"},{"key":"BFcddis2015129_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-065X.2007.00573.x","volume":"220","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47\u201359.","journal-title":"Immunol Rev"},{"key":"BFcddis2015129_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.cdd.4402266","volume":"15","author":"E Ullrich","year":"2008","unstructured":"Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L . Tumor stress, cell death and the ensuing immune response. Cell Death Differ 2008; 15: 21\u201328.","journal-title":"Cell Death Differ"},{"key":"BFcddis2015129_CR11","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","volume":"71","author":"J Fucikova","year":"2011","unstructured":"Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71: 4821\u20134833.","journal-title":"Cancer Res"},{"key":"BFcddis2015129_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00441-010-1033-1","volume":"343","author":"A Castiglioni","year":"2011","unstructured":"Castiglioni A, Canti V, Rovere-Querini P, Manfredi AA . High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res 2011; 343: 189\u2013199.","journal-title":"Cell Tissue Res"},{"key":"BFcddis2015129_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1189\/jlb.0306180","volume":"81","author":"D Yang","year":"2007","unstructured":"Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ . High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007; 81: 59\u201366.","journal-title":"J Leukoc Biol"},{"key":"BFcddis2015129_CR14","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1074\/jbc.M306793200","volume":"279","author":"JS Park","year":"2004","unstructured":"Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370\u20137377.","journal-title":"J Biol Chem"},{"key":"BFcddis2015129_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1189\/jlb.0306171","volume":"81","author":"IE Dumitriu","year":"2007","unstructured":"Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P . The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007; 81: 84\u201391.","journal-title":"J Leukoc Biol"},{"key":"BFcddis2015129_CR16","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1038\/cddis.2013.156","volume":"4","author":"O Krysko","year":"2013","unstructured":"Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV . Many faces of DAMPs in cancer therapy. Cell Death Dis 2013; 4: e631.","journal-title":"Cell Death Dis"},{"key":"BFcddis2015129_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/0008-5472.CAN-09-3566","volume":"70","author":"L Aymeric","year":"2010","unstructured":"Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70: 855\u2013858.","journal-title":"Cancer Res"},{"key":"BFcddis2015129_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.7150\/jca.5046","volume":"4","author":"Y Ma","year":"2013","unstructured":"Ma Y, Shurin GV, Peiyuan Z, Shurin MR . Dendritic cells in the cancer microenvironment. J Cancer 2013; 4: 36\u201344.","journal-title":"J Cancer"},{"key":"BFcddis2015129_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/CJI.0b013e3181880f1e","volume":"31","author":"JS Moyer","year":"2008","unstructured":"Moyer JS, Li J, Wei S, Teitz-Tennenbaum S, Chang AE . Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinoma. J Immunother 2008; 31: 885\u2013895.","journal-title":"J Immunother"},{"key":"BFcddis2015129_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CJI.0b013e318163628c","volume":"31","author":"S Teitz-Tennenbaum","year":"2008","unstructured":"Teitz-Tennenbaum S, Li Q, Okuyama R, Davis MA, Sun R, Whitfield J et al. Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother 2008; 31: 345\u2013358.","journal-title":"J Immunother"},{"key":"BFcddis2015129_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e318215e300","volume":"34","author":"CE Fadul","year":"2011","unstructured":"Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011; 34: 382\u2013389.","journal-title":"J Immunother"},{"key":"BFcddis2015129_CR22","doi-asserted-by":"publisher","first-page":"9851","DOI":"10.1073\/pnas.1101053108","volume":"108","author":"PM Krawczyk","year":"2011","unstructured":"Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 2011; 108: 9851\u20139856.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2015129_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3109\/02656736.2012.677933","volume":"28","author":"B Frey","year":"2012","unstructured":"Frey B, Weiss EM, Rubner Y, Wunderlich R, Ott OJ, Sauer R et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia 2012; 28: 528\u2013542.","journal-title":"Int J Hyperthermia"},{"key":"BFcddis2015129_CR24","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1038\/cddis.2012.161","volume":"3","author":"RA Anvekar","year":"2012","unstructured":"Anvekar RA, Asciolla JJ, Lopez-Rivera E, Floros KV, Izadmehr S, Elkholi R et al. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis 2012; 3: e420.","journal-title":"Cell Death Dis"},{"key":"BFcddis2015129_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/onci.1.1.17645","volume":"1","author":"L Zitvogel","year":"2012","unstructured":"Zitvogel L, Kroemer G . OncoImmunology: a new journal at the frontier between oncology and immunology. Oncoimmunology 2012; 1: 1\u20132.","journal-title":"Oncoimmunology"},{"key":"BFcddis2015129_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nrm2970","volume":"11","author":"P Vandenabeele","year":"2010","unstructured":"Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G . Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700\u2013714.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFcddis2015129_CR27","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/cdd.2009.184","volume":"17","author":"T Vanden Berghe","year":"2010","unstructured":"Vanden Berghe T, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N et al. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ 2010; 17: 922\u2013930.","journal-title":"Cell Death Differ"},{"key":"BFcddis2015129_CR28","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1084\/jem.187.9.1477","volume":"187","author":"D Vercammen","year":"1998","unstructured":"Vercammen D, Beyaert R, Denecker G, Goossens V, Van Loo G, Declercq W et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 1998; 187: 1477\u20131485.","journal-title":"J Exp Med"},{"key":"BFcddis2015129_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ceb.2009.12.003","volume":"22","author":"DE Christofferson","year":"2010","unstructured":"Christofferson DE, Yuan J . Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 2010; 22: 263\u2013268.","journal-title":"Curr Opin Cell Biol"},{"key":"BFcddis2015129_CR30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMra022366","volume":"348","author":"RM Friedlander","year":"2003","unstructured":"Friedlander RM . Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003; 348: 1365\u20131375.","journal-title":"N Engl J Med"},{"key":"BFcddis2015129_CR31","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/1535-7163.MCT-08-0893","volume":"8","author":"L Moretti","year":"2009","unstructured":"Moretti L, Kim KW, Jung DK, Willey CD, Lu B, Hwang M et al. Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor. Mol Cancer Ther 2009; 8: 1270\u20131279.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2015129_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1158\/1078-0432.CCR-05-0210","volume":"12","author":"SH Ko","year":"2006","unstructured":"Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab OI, Abdel-Wahab Z et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 2006; 12: 289\u2013297.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2015129_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/b102187","volume-title":"Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases","author":"M Los","year":"2005","unstructured":"Los M, Gibson SB . Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Springer: US, 2005."},{"key":"BFcddis2015129_CR34","first-page":"21","volume":"21","author":"S Triantopoulou","year":"2012","unstructured":"Triantopoulou S, Efstathopoulos E, Platoni K, Uzunoglou N, Kelekis N, Kouloulias V . Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters. Clin Transl Oncol 2012; 21: 21.","journal-title":"Clin Transl Oncol"},{"key":"BFcddis2015129_CR35","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1172\/JCI35180","volume":"118","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Andr\u00e9 F, Tesniere A, Kroemer G . The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118: 1991\u20132001.","journal-title":"J Clin Invest"},{"key":"BFcddis2015129_CR36","doi-asserted-by":"publisher","first-page":"10729","DOI":"10.1073\/pnas.0601956103","volume":"103","author":"P Schnorrer","year":"2006","unstructured":"Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, El-Sukkari D et al. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci USA 2006; 103: 10729\u201310734.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2015129_CR37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ijrobp.2010.12.071","volume":"80","author":"N Khan","year":"2011","unstructured":"Khan N, Khan MK, Almasan A, Singh AD, Macklis R . The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys 2011; 80: 645\u2013654.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFcddis2015129_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/02656739609023685","volume":"12","author":"J Overgaard","year":"1996","unstructured":"Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12: 3\u201320.","journal-title":"Int J Hyperthermia"},{"key":"BFcddis2015129_CR39","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/sj.cdd.4402163","volume":"14","author":"KG Wolter","year":"2007","unstructured":"Wolter KG, Verhaegen M, Fernandez Y, Nikolovska-Coleska Z, Riblett M, de la Vega CM et al. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 2007; 14: 1605\u20131616.","journal-title":"Cell Death Differ"},{"key":"BFcddis2015129_CR40","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.2174\/138920112800784989","volume":"13","author":"V Jendrossek","year":"2012","unstructured":"Jendrossek V . The intrinsic apoptosis pathways as a target in anticancer therapy. Curr Pharm Biotechnol 2012; 13: 1426\u20131438.","journal-title":"Curr Pharm Biotechnol"},{"key":"BFcddis2015129_CR41","doi-asserted-by":"publisher","first-page":"e9103","DOI":"10.1371\/journal.pone.0009103","volume":"5","author":"A Iwata","year":"2010","unstructured":"Iwata A, Morgan-Stevenson V, Schwartz B, Liu L, Tupper J, Zhu X et al. Extracellular BCL2 proteins are danger-associated molecular patterns that reduce tissue damage in murine models of ischemia-reperfusion injury. PloS One 2010; 5: e9103.","journal-title":"PloS One"},{"key":"BFcddis2015129_CR42","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1365-2036.2010.04264.x","volume":"31","author":"ML Shiffman","year":"2010","unstructured":"Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M, Burgess G . Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010; 31: 969\u2013978.","journal-title":"Aliment Pharmacol Ther"},{"key":"BFcddis2015129_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcp.24118","volume":"228","author":"S Palumbo","year":"2013","unstructured":"Palumbo S, Comincini S . Autophagy and ionizing radiation in tumors: the \"survive or not survive\" dilemma. J Cell Physiol 2013; 228: 1\u20138.","journal-title":"J Cell Physiol"},{"key":"BFcddis2015129_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cryobiol.2013.06.007","volume":"67","author":"IJ Tapia","year":"2013","unstructured":"Tapia IJ, Aris M, Arriaga JM, Blanco PA, Mazzobre F, Vega J et al. Development of a novel methodology for cryopreservation of melanoma cells applied to CSF470 therapeutic vaccine. Cryobiology 2013; 67: 163\u2013169.","journal-title":"Cryobiology"},{"key":"BFcddis2015129_CR45","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0092-8674(03)00422-7","volume":"113","author":"K Lauber","year":"2003","unstructured":"Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003; 113: 717\u2013730.","journal-title":"Cell"},{"key":"BFcddis2015129_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/cdd.2010.72","volume":"18","author":"YT Wu","year":"2011","unstructured":"Wu YT, Tan HL, Huang Q, Sun XJ, Zhu X, Shen HM . zVAD-induced necroptosis in L929 cells depends on autocrine production of TNFalpha mediated by the PKC-MAPKs-AP-1 pathway. Cell Death Differ 2011; 18: 26\u201337.","journal-title":"Cell Death Differ"},{"key":"BFcddis2015129_CR47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.immuni.2013.06.018","volume":"39","author":"JM Murphy","year":"2013","unstructured":"Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39: 443\u2013453.","journal-title":"Immunity"},{"key":"BFcddis2015129_CR48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fonc.2012.00132","volume":"2","author":"EM Weiss","year":"2012","unstructured":"Weiss EM, Wunderlich R, Ebel N, Rubner Y, Schlucker E, Meyer-Pittroff R et al. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol 2012; 2: 132.","journal-title":"Front Oncol"},{"key":"BFcddis2015129_CR49","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1089\/ars.2012.5143","volume":"20","author":"DS Pisetsky","year":"2014","unstructured":"Pisetsky DS . The translocation of nuclear molecules during inflammation and cell death. Antioxidants & redox signaling 2014; 20: 1117\u20131125.","journal-title":"Antioxidants & redox signaling"},{"key":"BFcddis2015129_CR50","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1089\/ars.2010.3341","volume":"15","author":"M Vezzoli","year":"2011","unstructured":"Vezzoli M, Castellani P, Corna G, Castiglioni A, Bosurgi L, Monno A et al. High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal 2011; 15: 2161\u20132174.","journal-title":"Antioxid Redox Signal"},{"key":"BFcddis2015129_CR51","doi-asserted-by":"publisher","first-page":"C917","DOI":"10.1152\/ajpcell.00401.2005","volume":"290","author":"JS Park","year":"2006","unstructured":"Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290: C917\u2013C924.","journal-title":"Am J Physiol Cell Physiol"},{"key":"BFcddis2015129_CR52","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.crvi.2004.04.002","volume":"327","author":"S Akira","year":"2004","unstructured":"Akira S, Takeda K . Functions of toll-like receptors: lessons from KO mice. C R Biol 2004; 327: 581\u2013589.","journal-title":"C R Biol"},{"key":"BFcddis2015129_CR53","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1016\/S0021-9258(18)34863-4","volume":"257","author":"JF Laliberte","year":"1982","unstructured":"Laliberte JF, St-Jean P, Beaudoin AR . Kinetic effects of Ca2+ and Mg2+ on ATP hydrolysis by the purified ATP diphosphohydrolase. J Biol Chem 1982; 257: 3869\u20133874.","journal-title":"J Biol Chem"},{"key":"BFcddis2015129_CR54","doi-asserted-by":"publisher","first-page":"e1102","DOI":"10.1038\/cddis.2014.70","volume":"5","author":"A Cauwels","year":"2014","unstructured":"Cauwels A, Rogge E, Vandendriessche B, Shiva S, Brouckaert P . Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell Death Dis 2014; 5: e1102.","journal-title":"Cell Death Dis"},{"key":"BFcddis2015129_CR55","doi-asserted-by":"publisher","first-page":"32608","DOI":"10.1074\/jbc.273.49.32608","volume":"273","author":"M Garcia-Calvo","year":"1998","unstructured":"Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA . Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998; 273: 32608\u201332613.","journal-title":"J Biol Chem"},{"key":"BFcddis2015129_CR56","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00262-014-1553-8","volume":"63","author":"V Umansky","year":"2014","unstructured":"Umansky V, Shevchenko I, Bazhin AV, Utikal J . Extracellular adenosine metabolism in immune cells in melanoma. Cancer Immunol Immunother 2014; 63: 1073\u20131080.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcddis2015129_CR57","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","volume":"192","author":"JM den Haan","year":"2000","unstructured":"den Haan JM, Lehar SM, Bevan MJ . CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192: 1685\u20131696.","journal-title":"J Exp Med"},{"key":"BFcddis2015129_CR58","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862\u2013870.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFcddis2015129_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","volume":"1","author":"EB Golden","year":"2013","unstructured":"Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC . An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013; 1: 365\u2013372.","journal-title":"Cancer Immunol Res"},{"key":"BFcddis2015129_CR60","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925\u2013931.","journal-title":"N Engl J Med"},{"key":"BFcddis2015129_CR61","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.radonc.2011.05.056","volume":"101","author":"P Schildkopf","year":"2011","unstructured":"Schildkopf P, Frey B, Ott OJ, Rubner Y, Multhoff G, Sauer R et al. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother Oncol 2011; 101: 109\u2013115.","journal-title":"Radiother Oncol"},{"key":"BFcddis2015129_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-1-59745-396-7_14","volume":"531","author":"U Schleicher","year":"2009","unstructured":"Schleicher U, Bogdan C . Generation, culture and flow-cytometric characterization of primary mouse macrophages. Methods Mol Biol 2009; 531: 203\u2013224.","journal-title":"Methods Mol Biol"},{"key":"BFcddis2015129_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","volume":"223","author":"MB Lutz","year":"1999","unstructured":"Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77\u201392.","journal-title":"J Immunol Methods"},{"key":"BFcddis2015129_CR64","unstructured":"Geran RI, Greenberg NH, Macdonald MM, Abbott BJ . Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI. Natl Cancer Inst Monogr 1977: 151\u2013153."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2015129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2015129","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2015129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T23:51:34Z","timestamp":1717890694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2015129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,14]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5]]}},"alternative-id":["BFcddis2015129"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2015.129","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,14]]},"assertion":[{"value":"22 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}